Recursion Pharmaceuticals share price logo

Recursion Pharmaceuticals

NASDAQ: RXRX

Small Cap

$3.49

-0.07

(-1.97%)

as on

Recursion Pharmaceuticals Stock Performance

as on August 27, 2026 at 2:15 pm IST

  • Day's Low

    Day's High

    $3.43
    $3.55
    downward going graph

    1.72%

    Downside

    1.72%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $2.77
    $7.18
    downward going graph

    20.63%

    Downside

    105.73%

    Upside

    downward going graph

Recursion Pharmaceuticals share price movements today

Previous Close
$3.56
Open
$3.50
Volume
12.1M
Market Cap
$1.7B
Day's Low - High
$3.43 - $3.55
52 Week Low - High
$2.77 - $7.18

Recursion Pharmaceuticals Historical Returns

1 Month Return
+ 18.27 %
3 Month Return
+ 12.3 %
1 Year Return
-27.2 %
3 Year Return
-58.26 %
5 Year Return
-84.18 %

Recursion Pharmaceuticals Stock Fundamentals & Key Indicators

Check Recursion Pharmaceuticals market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$1.7B

EPS (TTM)

-0.9227

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-471.6M

Revenue (TTM)

54.9M

Profit Margin

0.00%

Return On Equity TTM

-56.58%

Recursion Pharmaceuticals vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Recursion Pharmaceuticals with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
BUY$1.7B-84.18%NA0.00%NA
BUY$45.3B641.42%NA0.00%NA
BUY$138.8B176.54%31.9535.00%NA
BUY$55.4B-58.45%NA-141.43%NA
BUY$85.3B25.67%20.6227.87%44.39%

Stock Returns calculator for Recursion Pharmaceuticals Stock including INR - Dollar returns

The Recursion Pharmaceuticals stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

Recursion Pharmaceuticals investment value today

Current value as on today

₹77,696

Returns

-₹22,304

(-22.3%)

Returns from Recursion Pharmaceuticals Stock

-₹28,630 (-28.63%)

Dollar Impact

₹6,326 (+6.33%)

Analyst Recommendation on Recursion Pharmaceuticals Stock

Based on 4 analysts

BUY

25.00%

Buy

75.00%

Hold

0.00%

Sell

Based on 4 analysts, 75% of analysts recommend a 'BUY' rating for Recursion Pharmaceuticals. Average target price of $7.22

Recursion Pharmaceuticals Share Price Target

Get share price movements and forecasts by analysts on Recursion Pharmaceuticals.

What analysts predicted

51.66%UPSIDE

Target Price

$7.22

Current Price

$3.49

Analyzed by

4 Analysts

Target

$7.22

Recursion Pharmaceuticals target price $7.22, a slight upside of 51.66% compared to current price of $3.49. According to 4 analysts rating.

Indian Investors' Interest in Recursion Pharmaceuticals Stock

Investment in Recursion Pharmaceuticals Shares on INDmoney has dropped by -23.04% in the last 30 days, indicating reduced investment activity.

Time period: to

Change:-23.04% versus previous 30 day period

Search interest for Recursion Pharmaceuticals Stock has decreased by -15% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-15% versus previous 30 day period

Recursion Pharmaceuticals Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
13
14
26
4
14
19
5
35
6
7
Gross Profit
2
5
14
-8
-7
-1
-24
8
-6
-3
Operating Income
-96
-100
-98
-183
-191
-176
-172
-108
-128
-134
EBITDA
-84
-88
-87
-165
-182
-147
-141
-88
-102
-112
Interest Expense
0
0
0
0
0
0
0
0
0
0
Depreciation
7
8
7
12
19
23
21
19
19
18
Income Before Tax
-92
-98
-95
-178
-202
-171
-162
-108
-122
-131
Income Tax Expense
0
0
0
0
0
-
0
0
-4
0
Net Income
-91
-97
-95
-178
-202
-171
-162
-108
-117
-131
Net Profit Margin
-677.29%
-677.17%
-366.82%
-3965.99%
-1373.26%
-899.84%
-3135.32%
-304.25%
-1815.57%
-1708.02%

Recursion Pharmaceuticals Annual Profit & Loss

All numbers in Millions USD

Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
1
3
10
39
43
58
74
Gross Profit
-44
3
10
-8
1
13
-46
Operating Income
-62
-84
-182
-245
-350
-479
-648
EBITDA
-58
-81
-174
-233
-307
-426
-559
Interest Expense
0
1
2
0
0
1
1
Depreciation
3
4
8
11
20
36
83
Income Before Tax
-61
-87
-186
-239
-332
-464
-644
Income Tax Expense
0
0
-8
0
-4
-1
0
Net Income
-62
-87
-178
-239
-328
-463
-644
Net Profit Margin
-3654.30%
-2549.25%
-1780.74%
-603.36%
-747.71%
-788.02%
-863.35%

Recursion Pharmaceuticals Quarterly Cash Flow

All numbers in Millions USD

Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-97
-95
-178
-202
-171
-162
-108
-117
-131
Operating Cash Flow
-82
-59
-115
-131
-76
-117
-46
-81
-105
Investing Cash Flow
-4
-4
275
-7
-5
-2
-1
0
-1
Financing Cash Flow
263
16
10
40
97
251
132
-3
-1
Change in Cash
176
-46
167
-93
24
133
86
-88
-108

Recursion Pharmaceuticals Annual Cash Flow

All numbers in Millions USD

Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-87
-186
-239
-328
-463
-644
Operating Cash Flow
-45
-158
-83
-287
-359
-371
Investing Cash Flow
-8
-271
193
-10
260
-16
Financing Cash Flow
246
458
154
140
304
521
Change in Cash
191
28
263
-157
201
150

Mutual Funds that own Recursion Pharmaceuticals Stock

Check out the Mutual Funds with significant holdings in Recursion Pharmaceuticals.

Funds
Holdings
Shares Held
VANGUARD INDEX FUNDS
7.317616%
39174286
Fidelity Concord Street Trust
1.016916%
5443981
Fidelity Salem Street Trust
0.926666%
4960835
VANGUARD WORLD FUND
0.814014%
4357765
VANGUARD EXPLORER FUND
0.437173%
2340373

Global Institutional Holdings in Recursion Pharmaceuticals

Funds
Holdings
Vanguard
8.41%
Cathie Wood
7.72%
ARK
6.87%
SPDR
4.83%
iShares
4.69%

Recursion Pharmaceuticals News & Key Events

  • img

    Today's Timeline - 17 August

    Mon, 10:31 AM

    -

    Recursion Pharmaceuticals highlights AI platform advancements, pipeline updates, and collaborations with Roche and Sanofi during a BofA Global Research conference.

    Mon, 07:26 PM

    -

    RXRX shares down 22.8% YTD; REC-4881 shows promise in reducing polyp burden, with FDA discussions ongoing for pivotal trial.

Insights on Recursion Pharmaceuticals

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, RXRX stock has moved up by 4.5%

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 6.47M → 7.67M (in $), with an average increase of 15.6% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Revolution Medicines, Inc. Common Stock has given 33.7% return, outperforming this stock by 92.8%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 496.3% return, outperforming this stock by 524.9%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 3 quarters, -108.12M → -131.00M (in $), with an average decrease of 10.1% per quarter

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
OrganisationRecursion Pharmaceuticals
Headquarters41 South Rio Grande Street, Salt Lake City, UT, United States, 84101
IndustryBiotechnology
CEODr. Najat Khan Ph.D.
E-voting on sharesClick here to vote

Key Management of Recursion Pharmaceuticals

Name

Title

Mr. Benjamin Mabey M.S.

Chief Technology Officer

Mr. Nathan Hatfield J.D., M.B.A.

Chief Legal Officer & Corporate Secretary

Mr. Ryan Kelly

Chief Communications Officer

Ms. Erica Fox

Chief People and Impact Officer

Mr. Matthew Kinn M.B.A.

Chief Business Officer

Mr. Sid Jain

Senior Vice President of Clinical Development & Data Science

Dr. Vicki L. Goodman M.D.

Chief Medical Officer

Dr. Najat Khan Ph.D.

CEO, President & Director

Mr. Ben R. Taylor

CFO & President of Recursion UK

Dr. David Hallett Ph.D.

Chief Scientific Officer

FAQs

What is Recursion Pharmaceuticals share price today?

Recursion Pharmaceuticals share price today is $3.49 as on at the close of the market. Recursion Pharmaceuticals share today touched a day high of $3.55 and a low of $3.43.

What is the 52 week high and 52 week low for Recursion Pharmaceuticals share?

Recursion Pharmaceuticals share touched a 52 week high of $7.18 on and a 52 week low of $2.77 on . Recursion Pharmaceuticals stock price today i.e. is closed at $3.49,which is 51.39% down from its 52 week high and 25.99% up from its 52 week low.

What is Recursion Pharmaceuticals's market capitalisation today?

Recursion Pharmaceuticals market capitalisation is $0.00T as on .

How to invest in Recursion Pharmaceuticals Stock (RXRX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Recursion Pharmaceuticals on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Recursion Pharmaceuticals Shares that will get you 0.4298 shares as per Recursion Pharmaceuticals share price of $3.49 per share as on August 27, 2026 at 8:45 am IST.

What is the minimum amount required to buy Recursion Pharmaceuticals Stock (RXRX) from India?

Indian investors can start investing in Recursion Pharmaceuticals (RXRX) shares with as little as ₹95.402 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹954.02 in Recursion Pharmaceuticals stock (as per the Rupee-Dollar exchange rate as on ). Based on Recursion Pharmaceuticals share’s latest price of $3.49 as on August 27, 2026 at 8:45 am IST, you will get 2.8653 shares of Recursion Pharmaceuticals. Learn more about fractional shares .

What are the returns that Recursion Pharmaceuticals has given to Indian investors in the last 5 years?

Recursion Pharmaceuticals stock has given -84.18% share price returns and 29.12% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?